A resolution designating the week of May 1, 2023, through May 7, 2023, as "Tardive Dyskinesia Awareness Week".
The resolution is expected to raise public consciousness about Tardive Dyskinesia and its relationship with mental health treatments. By designating a specific week for awareness, it aims to encourage discussions about the condition and promote regular screenings for those who may be at risk. The Senate's action can have a positive influence on advocacy efforts for better recognition and management of Tardive Dyskinesia, potentially leading to improved healthcare policies and support for affected individuals.
SR197 is a resolution designating the week of May 1, 2023, through May 7, 2023, as 'Tardive Dyskinesia Awareness Week.' The resolution emphasizes the need for increased awareness of Tardive Dyskinesia, a movement disorder that can result from long-term treatment with dopamine receptor blocking agents, such as antipsychotic medications used for various mental health conditions. The bill aims to educate the public and medical community on the risks and long-term effects associated with Tardive Dyskinesia, highlighting the challenges faced by affected individuals and their caregivers.
While SR197 primarily serves an educational purpose, it brings to light the broader discussions surrounding mental health treatment and the side effects associated with various medications. There may be contentious dialogue around the adequacy of current treatments for those impacted by Tardive Dyskinesia, especially amid calls for better management options. Furthermore, the resolution highlights the stigma faced by patients living with Tardive Dyskinesia, which may catalyze further advocacy for improvements in mental health care practices.